{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:45:22Z","timestamp":1791247522629,"version":"4.1.0"},"reference-count":17,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Skin toxicity is frequent and debilitating in oncologic patients treated with epidermal growth factor receptor inhibitors (EGFRIs). Grading and management of skin adverse events (AEs) are poorly standardized. &lt;b&gt;&lt;i&gt;Materials and Methods:&lt;\/i&gt;&lt;\/b&gt; We developed a new score (EGFRISTI: Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index) which is able to quantify and monitor all EGFRI-related dermatologic AEs over time. The utility of this tool was validated in 130 patients treated with 5 different EGFRIs including both monoclonal antibodies and tyrosine kinase inhibitors. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; The mean baseline EGFRISTI score was 26.9 (range: 6.0-64.5). Mild toxicity was found in 55 patients (42.3%), moderate toxicity in 43 (33.1%), and severe toxicity in 32 patients (24.6%). After the first-line toxicity treatment, an EGFRISTI score reduction of &gt;75% was obtained in 31 patients (34.1%) and one of 50% in 40 patients (43.9%), while an improvement of &lt;50% was observed in the remaining 20 subjects (22.0%). &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; The EGFRISTI is a simple and reliable tool to quantify and express the severity of all clinical signs and symptoms of EGFRI skin toxicity with a single numerical value, to choose the most suitable therapy, and to measure its efficacy.<\/jats:p>","DOI":"10.1159\/000365994","type":"journal-article","created":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T07:51:59Z","timestamp":1410249119000},"page":"311-319","source":"Crossref","is-referenced-by-count":7,"title":["The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): A New Tool for Grading and Managing Skin Adverse Reactions to Epidermal Growth Factor Receptor Inhibitors"],"prefix":"10.1159","volume":"87","author":[{"given":"Paolo","family":"Lisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2014,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707704"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25090"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1623-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-5-345"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055128"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1404-0"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp439"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.11.016"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1645-y"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1197-6"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0744-x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2008.00715.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/9781118032923.ch1"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000277656"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/365994","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/365994","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/365994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:34:09Z","timestamp":1745429649000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000365994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,30]]}},"URL":"https:\/\/doi.org\/10.1159\/000365994","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}